Venture Atlas

Airbus said deliveries of its A330neo widebody have resumed after a quality lapse in the tail section, a tool left inside a horizontal tail plane during production, brought handovers to a near standstill for three months, Bloomberg reported September 3, 2026. The manufacturer delivered zero A330neos in June and July and just one in August, versus a typical pace of about four a month, before calling the root cause identified and the issue isolated. Airbus still aims to ramp output to five A330neos a month by 2029 as it works toward roughly 870 total aircraft deliveries in 2026.

Li Auto put a new-generation Li MEGA on sale in China on September 2, 2026, offering only a Home trim priced at RMB509,800 (about $71,600), roughly RMB50,000 below the prior Home version, in a bid to revive volume for the flagship that pioneered its battery-electric lineup. The refreshed seven-seat MPV pairs a 108 kWh CATL battery good for 710 km of range with a 413 kW dual-motor powertrain, a 4-lidar sensor suite and Li Auto's new Mahe VLA driving model, plus an air-suspension chassis with active anti-roll control.

Unitree Robotics shares tumbled as much as 4.3% to 546.51 yuan on September 2, 2026, leaving the stock more than 50% below the 1,100 yuan intraday high it hit on its August 19 Shanghai STAR Market debut, when shares initially surged 460% after a 6.1 billion yuan ($904 million) IPO. The reversal follows first-quarter 2026 adjusted net profit that fell 53% year over year and renewed scrutiny of how much of Unitree's humanoid-robot revenue still comes from research and education customers rather than industrial deployment, fueling debate over a Chinese robotics valuation bubble.

BioNTech said on August 28, 2026 it is terminating the Phase 2 BNT122-01 trial of its individualized mRNA cancer vaccine autogene cevumeran as an adjuvant monotherapy in surgically resected, ctDNA-positive colorectal cancer, run with Genentech. An independent Data Safety Monitoring Board recommended stopping after finding a numerical imbalance in overall survival between the vaccine and watchful-waiting arms and judging further continuation unlikely to change the outcome, though it reported no new safety signal. BioNTech said the separate Phase 2 IMcode003 trial testing autogene cevumeran in combination with chemotherapy and checkpoint inhibition for pancreatic cancer is unaffected and continues as planned.